Daiichi Sankyo Europe plans to create a European trial registry for atrial fibrillation (AF) from existing records of 5,000 AF patients in seven EU countries.
It is hoped that the data gathered by the PREFER in AF registry will enable clinicians to assess the effectiveness of new treatments.
The accumulation of ‘real life data’ is aimed to fill the ‘knowledge gaps’ on AF management identified in a 2010 World Heart Foundation paper.
The registry will include data on the comparison between valvular and non-valvular forms of AF, the impact of new anticoagulants on stroke prevention, and the effect of AF treatment on quality of life.
AF affects up to 2% of the European population, and is a common cause of stroke.
The new database will be a multi-centre, prospective observational disease registry with a one-year follow up, covering all AF patient groups.
The data will be collected from Austria, France, Germany, Italy, Spain, Switzerland and the UK; it will cover stroke prevention management approaches in terms of health economics, patient satisfaction and quality of life.
Professor José Luis Zamorano of the University Clinic San Carlos, Madrid, Spain, co-chair of the study’s steering committee, said: “This essential patient registry is important as it is focused on patients’ quality of life and treatment satisfaction, which are key factors when considering optimal patient care.
“AF is a condition associated with high morbidity and mortality and when patients are satisfied with their treatment, they stay on treatment.”